Connection between Radiographic Progression and Patient Related Outcomes
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nuclear Medicine & Radiology".
Deadline for manuscript submissions: closed (30 June 2021) | Viewed by 279
Special Issue Editor
2. Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians-University, Munich, Germany
Interests: rheumatoid arthritis; treat to target; biological DMARDs; synthetical DMARDs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Rheumatoid arthritis is a chronic inflammatory disease that primarily affects the joints. In general, joint inflammation leads to joint destruction, and, subsequently, to disability. All of the drugs registered for treatment of RA over the last two decades have been to significantly inhibit both inflammation and destruction.
Disability can be assessed with specifically designed patient-reported outcomes, such as HAQ-DI and SF36. However, there are data supporting the notion that the HAQ-DI can be understood as a score driven in part by disease activity, and in part by joint destruction. Therefore, the direct connection between joint destruction and disability has not been conclusively established.
The aim of this Special Issue is to analyze and illustrate the connection and interaction between these factors with respect to disease activity.
Dr. Rüdiger Müller
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Rheumatoid arthritis
- Joint destruction/progression
- Patient-related outcomes
- Connection
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
